Up to 25% of ECs demonstrate disruption of the MMR pathway, revealed by high MSI and/or loss of MMR protein expression (MMR-deficiency) by immunohistochemistry (IHC). This evidence concerns the gene MRC1 and mismatch repair cancer syndrome 1.